AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34464408 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned delivery mode
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical support and positive childbirth experience
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive birth experience
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Path modeling
Number of subjects: 284
Study 34464523 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Therapy
Number of subjects: 0
Study 34464547 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted arcuate incisions using the Castrop nomogram
Number of subjects: 19
Study 34464961 — intervention group
Group type: EXPERIMENTAL
Intervention: DFOS-IT
Number of subjects: 265
Study 34465123 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary score
Number of subjects: 10385
Study 34465123 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ subdomains
Number of subjects: 10385
Study 34465123 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ scores
Number of subjects: 10385
Study 34465132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0
Study 34465132 — intervention group
Group type: COMPARATOR
Intervention: High-power, short-duration radiofrequency ablation
Number of subjects: 0
Study 34465131 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplant Perceived Stress Scale score
Number of subjects: 96
Study 34465131 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months Perceived Stress Scale score
Number of subjects: 96
Study 34465131 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher Perceived Stress Scale score at 6 months
Number of subjects: 96
Study 34465131 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis themes
Number of subjects: 96
Study 34465131 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies employed by caregivers
Number of subjects: 96
Study 34465185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 628
Study 34465185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural patients (after adjusting for demographics, depression severity, and physical functioning)
Number of subjects: 628
Study 34465306 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Number of subjects: 475
Study 34465306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigation strategies including higher than expected student mask compliance, reduced room capacity, and phased reopening
Number of subjects: 475
Study 34465348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without new in-brace x-rays with major brace adjustments or new brace fabrication
Number of subjects: 90
Study 34465348 — intervention group
Group type: COMPARATOR
Intervention: Patients with new in-brace x-rays with major brace adjustments or new brace fabrication
Number of subjects: 90
Study 34465452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cyclical treatment regimen of dydrogesterone 10 mg 2 or 3 times daily between the 5th and 25th days of the menstrual cycle
Number of subjects: 350
Study 34465452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment regimen of dydrogesterone 10 mg 2 or 3 times daily
Number of subjects: 350
Study 34465452 — intervention group
Group type: COMPARATOR
Intervention: Both treatment regimens (prolonged cyclical and continuous)
Number of subjects: 350
Study 34465457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lipid-rich plaques identified by near-infrared spectroscopy (maxLCBI)
Number of subjects: 0
Study 34465465 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ECG interpretation statements of acute MI or acute ischemia
Number of subjects: 2400
Study 34465599 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054 monotherapy
Number of subjects: 82
Study 34465599 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054/anti-TIM-3 combination
Number of subjects: 82
Study 34465694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8, 12, or 24 weeks
Number of subjects: 95
Study 34465694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Number of subjects: 95
Study 34466220 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade ureteral stent insertion
Number of subjects: 188
Study 34466711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-implemented chronotherapeutic restoring bundle
Number of subjects: 0
Study 34466711 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34466766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 1
Study 34466766 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of immunotherapy, surgery, external beam radiation
Number of subjects: 1
Study 34467247 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34467254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade of α4β7 and αEβ7
Number of subjects: 0
Study 34467254 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab treatment
Number of subjects: 0
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations
Number of subjects: 104
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1 mutations
Number of subjects: 104
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA2 mutations
Number of subjects: 104
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations in hormone receptor-positive MBC
Number of subjects: 104
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations in triple-negative MBC
Number of subjects: 104
Study 34467476 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR gene mutations
Number of subjects: 104
Study 34467530 — intervention group
Group type: COMPARATOR
Intervention: Intravenous atosiban
Number of subjects: 3733
Study 34467530 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous barusiban
Number of subjects: 3733
Study 34467530 — intervention group
Group type: COMPARATOR
Intervention: Oral nolasiban
Number of subjects: 3733
Study 34467774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (TRODELVY)
Number of subjects: 0
Study 34467774 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 0
Study 34468322 — intervention group
Group type: EXPERIMENTAL
Intervention: RECAP-V1 prediction model
Number of subjects: 3732
Study 34468322 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation on an independent dataset of 1400 patients
Number of subjects: 3732
Study 34468330 — intervention group
Group type: EXPERIMENTAL
Intervention: About Us intervention
Number of subjects: 533
Study 34468330 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 533
Study 34468332 — intervention group
Group type: EXPERIMENTAL
Intervention: The Secret Trail of Moon (TSTM) - a virtual reality serious video game for cognitive training related to ADHD symptoms.
Number of subjects: 37
Study 34468913 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry Guided Respiratory Intervention (CGRI)
Number of subjects: 0
Study 34468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent meningitis and extra-cerebral IPD
Number of subjects: 771
Study 34468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall IPD
Number of subjects: 771
Study 34468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, history of malignant solid tumor, meningeal IPD, and serotypes with high mortality potential
Number of subjects: 771
Study 34468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vaccine serotypes
Number of subjects: 771
Study 34468953 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitis patients
Number of subjects: 771
Study 34468963 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (voriconazole alone or sequential/combined therapy)
Number of subjects: 145
Study 34468963 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (voriconazole)
Number of subjects: 145
Study 34468963 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal voriconazole regimen (loading dose, 200 mg twice daily; daily maintenance dose, 100 mg)
Number of subjects: 145
Study 34468963 — intervention group
Group type: COMPARATOR
Intervention: ACLF patients with IPA
Number of subjects: 145
Study 34468973 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PHMS (Philadelphia Mindfulness Scale)
Number of subjects: 108
Study 34468973 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMS-Acceptance
Number of subjects: 108
Study 34468973 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMS-Awareness
Number of subjects: 108
Study 34469268 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observation of mild and moderate asthma
Number of subjects: 20000
Study 34469268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 20000
Study 34469268 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments over time
Number of subjects: 20000
Study 34469268 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-related functional and inflammatory patterns
Number of subjects: 20000
Study 34469268 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and lifestyle influences
Number of subjects: 20000
Study 34470049 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 800 mg, Carfilzomib 70 mg/m2, Dexamethasone 40 mg
Number of subjects: 49
Study 34470049 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 or 800 mg, Carfilzomib 27, 56, or 70 mg/m2, Dexamethasone 20 or 40 mg
Number of subjects: 49
Study 34470054 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular transfusion in adults
Number of subjects: 254
Study 34470054 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype in children
Number of subjects: 254
Study 34470054 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelation
Number of subjects: 254
Study 34470054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension
Number of subjects: 254
Study 34470054 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaundice symptom
Number of subjects: 254
Study 34470489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 248
Study 34470489 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 248
Study 34470489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with complete recanalization
Number of subjects: 248
Study 34470501 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based alcohol-mediated renal denervation
Number of subjects: 0
Study 34470501 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34470614 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 30 years or older
Number of subjects: 8509
Study 34470614 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BMI status and consistent multivitamin supplement intake
Number of subjects: 8509
Study 34470657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation from supine to standing position
Number of subjects: 24
Study 34470703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Sensitivity Cardiac Troponin I
Number of subjects: 0
Study 34470703 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34470826 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ40p53 isoform
Number of subjects: 0
Study 34470826 — intervention group
Group type: EXPERIMENTAL
Intervention: Netrin-1 interference
Number of subjects: 0
Study 34470826 — intervention group
Group type: EXPERIMENTAL
Intervention: Netrin-1 and Δ40p53 gene expression correlation
Number of subjects: 0
Study 34471234 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4 and anti-BCMA CAR co-modified NK cells
Number of subjects: 0
Study 34471234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34471346 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical surgery for esotropia
Number of subjects: 40
Study 34471346 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical surgery for esotropia
Number of subjects: 40
Study 34471346 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical surgery for exotropia
Number of subjects: 40
Study 34471346 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical surgery for exotropia
Number of subjects: 40
Study 34471447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Electro-Auricular Acupuncture
Number of subjects: 0
Study 34471447 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial Anesthesia
Number of subjects: 0
Study 34471639 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PED without coils
Number of subjects: 48
Study 34471639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversized PED placed from M1 to the ICA
Number of subjects: 48
Study 34471928 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity
Number of subjects: 1410
Study 34471928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low activity group
Number of subjects: 1410
Study 34471928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid activity group
Number of subjects: 1410
Study 34471928 — intervention group
Group type: EXPERIMENTAL
Intervention: High activity group
Number of subjects: 1410
Study 34472021 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMP intervention
Number of subjects: 151
Study 34472021 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 151
Study 34472035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 135
Study 34472035 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 135
Study 34472719 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy (ABC)
Number of subjects: 3393
Study 34472769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program combined with oral antioxidant therapy (multivitamins, coenzyme Q10, omega-3, and oligo-elements) for 3 months
Number of subjects: 93
Study 34472769 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy male volunteers)
Number of subjects: 93
Study 34472988 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAS classification
Number of subjects: 140
Study 34473061 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious health computer game promoting a healthy lifestyle
Number of subjects: 157
Study 34473061 — intervention group
Group type: COMPARATOR
Intervention: Regular classes (control)
Number of subjects: 157
Study 34473227 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) methods for classification of olfactory dysfunction
Number of subjects: 611
Study 34473227 — intervention group
Group type: COMPARATOR
Intervention: Traditional logistic regression for classification of olfactory dysfunction
Number of subjects: 611
Study 34473237 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs)
Number of subjects: 30
Study 34473237 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party VSTs
Number of subjects: 30
Study 34473237 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived VSTs
Number of subjects: 30
Study 34473237 — intervention group
Group type: EXPERIMENTAL
Intervention: VSTs from both donor sources
Number of subjects: 30
Study 34473258 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach and audit and feedback strategies
Number of subjects: 847
Study 34473258 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach
Number of subjects: 847
Study 34473258 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 847
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab (0.7 g)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab (2.8 g)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab (7.0 g)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab/etesevimab
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (2.4 g)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (8.0 g)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Sotrovimab
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Regdanvimab (40 mg/kg)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Regdanvimab (80 mg/kg)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab (hospitalised)
Number of subjects: 17495
Study 34473343 — intervention group
Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (hospitalised)
Number of subjects: 17495
Study 34473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs) and caregivers' perceptions of nutritional status
Number of subjects: 497
Study 34473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Motor Function Classification System (GMFCS) levels
Number of subjects: 497
Study 34473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about nutritional status
Number of subjects: 497
Study 34473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between HCP and caregiver perceptions
Number of subjects: 497
Study 34473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective nutritional status assessment
Number of subjects: 497
Study 34473594 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX™ (Varicella Virus Vaccine Live [Oka/Merck]) 0.5 mL, 2 doses 6 weeks apart
Number of subjects: 50
Study 34473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-chelate (Gd) enhanced dynamic MRI
Number of subjects: 134
Study 34473939 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34474014 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on organ transplantation rates
Number of subjects: 0
Study 34474014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant rate patterns
Number of subjects: 0
Study 34474014 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal trends in transplant activity
Number of subjects: 0
Study 34474164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab prior to alloSCT
Number of subjects: 9
Study 34474164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior ICI exposure)
Number of subjects: 9
Study 34474164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab prior to alloSCT with post-transplantation cyclophosphamide (PTCy)
Number of subjects: 9
Study 34474584 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 0
Study 34474584 — intervention group
Group type: COMPARATOR
Intervention: Thin-Strut Drug-Eluting Stents (DES)
Number of subjects: 0
Study 34474597 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microcirculatory dysfunction assessed by index of microcirculatory resistance (IMR)
Number of subjects: 154
Study 34474597 — intervention group
Group type: COMPARATOR
Intervention: Surveillance endomyocardial biopsy
Number of subjects: 154
Study 34474640 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and decitabine
Number of subjects: 0
Study 34474927 — intervention group
Group type: EXPERIMENTAL
Intervention: AVB-500 + PAC
Number of subjects: 53
Study 34474927 — intervention group
Group type: EXPERIMENTAL
Intervention: AVB-500 + PAC (subgroup with no prior bevacizumab or AVB-500 trough levels >13.8 mg/L)
Number of subjects: 53
Study 34474927 — intervention group
Group type: COMPARATOR
Intervention: AVB-500 + PLD
Number of subjects: 53
Study 34474932 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-based prototype application (CBPA) measuring pulse rate (PR)
Number of subjects: 446
Study 34474932 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry (reference method)
Number of subjects: 446
Study 34475142 — intervention group
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi)
Number of subjects: 200
Study 34475166 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal palpation of pelvic floor muscle function assessment
Number of subjects: 222
Study 34475166 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of involuntary contraction and voluntary relaxation
Number of subjects: 222
Study 34475166 — intervention group
Group type: EXPERIMENTAL
Intervention: Calliper measurement of diastasis recti abdominis width at umbilicus after 2 months of training
Number of subjects: 222
Study 34475166 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of diastasis recti abdominis depth and bulging
Number of subjects: 222
Study 34475172 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust network
Number of subjects: 2890
Study 34475172 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex network (trust and health advice)
Number of subjects: 2890
Study 34475172 — intervention group
Group type: COMPARATOR
Intervention: Health advice-only network
Number of subjects: 2890
Study 34475172 — intervention group
Group type: COMPARATOR
Intervention: Trust-only network
Number of subjects: 2890
Study 34475172 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CVD risk score (QRISK3)
Number of subjects: 2890
Study 34475174 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact
Number of subjects: 667
Study 34475253 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System
Number of subjects: 106
Study 34475253 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (Y-stenting technique)
Number of subjects: 106